We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Eli Lilly’s investigational, oral, first-in-class molecule lasmiditan has hit key targets a late-stage trial assessing its safety and efficacy as a treatment for acute migraine, raising hopes for a new approach to managing the condition